Rein Therapeutics presents late-breaking ERS poster on inhaled LTI-03 idiopathic pulmonary fibrosis dose-escalation trial

• Rein Therapeutics will present a late-breaking ERS 2026 poster on inhaled LTI-03 in idiopathic pulmonary fibrosis on Sept. 8.
• Results were already published in Nature Communications; the ERS presentation will bring the findings to a major medical meeting audience.
• The randomized dose-escalation study supports continued clinical development of LTI-03 in pulmonary fibrosis, an orphan market with high unmet need.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609040800PRIMZONEFULLFEED9821463) on September 04, 2026, and is solely responsible for the information contained therein.